Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 135

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Diffuse large B-cell lymphoma

Not yet recruiting

Phase II study of fixed‑dose, accelerated ramp‑up epcoritamab plus lenalidomide in patients with relapsed/refractory large B‑cell lymphoma after CAR‑T therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Clear cell renal cell carcinoma

Not yet recruiting

Phase I study of 161Tb-PSMA-1 therapy and gallium‑68 gozetotide imaging in adult patients with metastatic clear cell renal cell carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Centre Leon Berard

Neoplasm

Not yet recruiting

Study of sacituzumab govitecan versus investigator’s choice drug combination in patients with cancer of unknown primary after platinum‑based chemotherapy failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Non-small cell lung cancer stage III

Not yet recruiting

Fluorescence bronchoscopy to assess durvalumab-680LT distribution in unresectable stage III non‑small cell lung cancer patients after chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitair Medisch Centrum Groningen

Hormone receptor positive breast cancer

Not yet recruiting

Evaluating tirzepatide and letrozole for reducing tumor growth in postmenopausal hormone‑receptor‑positive breast cancer patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:UZ Leuven

Neuroendocrine carcinoma

Not yet recruiting

Phase II Study of BI 764532 Added to Platinum Chemotherapy in Adults with Advanced Large‑Cell Neuroendocrine Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Igg-Like T Cell Engager Binding To Dll3 And Cd3
  • Sponsor:Technische Universitat Dresden

Diffuse large B-cell lymphoma

Not yet recruiting

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Gastrooesophageal cancer

Not yet recruiting

Perioperative Zanidatamab and Tislelizumab with Chemotherapy for Patients with HER2‑Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:UZ Leuven

Sarcoma

Not yet recruiting

Evaluation of 68Ga-FAPI-46 and Fluor-18-FDG PET/MRI in Paediatric Sarcoma Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Rigshospitalet

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Posaconazole
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Non-small cell lung cancer

Not yet recruiting

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Invasive lobular breast carcinoma+1

Not yet recruiting

Diagnostic Accuracy of [68Ga]FAPI-46 PET/CT for Detecting Metastatic Lesions in Patients with Invasive Lobular Breast Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Hospices Civils De Lyon

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.